Program
alirocumab
Also written as “Alirocumab”, “alirocumab SAR236553 (REGN727)” and “Alirocumab SAR236553 (REGN727)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia · Atherosclerosis, led by 3 companies.
Drug pageAlirocumab: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 300 open or running | phase 4since Dec 24, 2015 | Feb 1, 2011 | none ahead |
| Regeneron Pharmaceuticalsits history only | 161 open or running | phase 4since Oct 28, 2016 | Nov 20, 2009 | Dec 29, 2026phase 2 · NCT07477704 |
| Kobe Universityits history only | 20 open or running | phase 4since May 7, 2018 | May 7, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Feb 1, 2011.
- Jan 30, 2013Phase 1 study in HypercholesterolemiaNCT01785329 · 60 enrolled · United Kingdom
- Mar 14, 2013Phase 2 study in HypercholesterolemiaNCT01812707 · 100 enrolled · Japan
- Sep 16, 2013Phase 3 study in HypercholesterolemiaNCT01954394 · 986 enrolled · United States, Argentina, Austria and more
- Oct 7, 2013Phase 1 study in HypercholesterolemiaNCT01959971 · 20 enrolled · United States
- Dec 6, 2013Phase 3 study in HypercholesterolemiaNCT02023879 · 233 enrolled · United States, Australia, Belgium and more
- Apr 4, 2014Phase 3 study in HypercholesterolemiaNCT02107898 · 216 enrolled · Japan
- Jun 16, 2015Phase 3 study in HypercholesterolemiaNCT02476006 · 998 enrolled · Austria, Belgium, Canada and more
- Oct 21, 20152 phase 3 studies in HypercholesterolemiaNCT02584504, NCT02585778
- Dec 24, 2015Phase 4 study in DyslipidemiasNCT02642159 · 413 enrolled · United States, Australia, Brazil and more
- Mar 16, 2016Phase 3 study in HypercholesterolemiaNCT02715726 · 615 enrolled · China, India, Thailand
- Aug 31, 2016Phase 2 study in HypercholesterolemiaNCT02890992 · 42 enrolled · United States, Canada, Czechia and more
- Nov 29, 2016Phase 1 study in HypercholesterolemiaNCT02979015 · 35 enrolled · China
- Dec 5, 2016Phase 4 study in HypercholesterolemiaNCT02984982 · 206 enrolled · Japan
- Apr 18, 20182 phase 3 studies in HypercholesterolemiaNCT03510884, NCT03510715
TargetBeta
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SYH2053rule | CSPC Pharmaceutical Group | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 30 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03510884Hypercholesterolemia · United States, Argentina, Austria and more | 3 | Completed | Jan 14, 2021 | 153 |
| NCT03510715Hypercholesterolemia · Brazil, Canada, Denmark and more | 3 | Completed | Feb 17, 2020 | 18 |
| NCT02984982Hypercholesterolemia · Japan | 4 | Completed | Jul 27, 2018 | 206 |
| NCT02979015Hypercholesterolemia · China | 1 | Completed | Nov 27, 2017 | 35 |
| NCT02890992Hypercholesterolemia · United States, Canada, Czechia and more | 2 | Completed | Sep 13, 2018 | 42 |
| NCT02715726Hypercholesterolemia · China, India, Thailand | 3 | Completed | Aug 6, 2018 | 615 |
| NCT02642159Dyslipidemias · United States, Australia, Brazil and more | 4 | Completed | Mar 22, 2017 | 413 |
| NCT02585778Hypercholesterolemia · United States, Austria, Belgium and more | 3 | Completed | Apr 3, 2017 | 517 |
| NCT02584504Hypercholesterolemia · Japan | 3 | Completed | Apr 5, 2017 | 163 |
| NCT02476006Hypercholesterolemia · Austria, Belgium, Canada and more | 3 | Completed | Apr 12, 2019 | 998 |
| NCT02107898Hypercholesterolemia · Japan | 3 | Completed | Jan 2015 | 216 |
| NCT02023879Hypercholesterolemia · United States, Australia, Belgium and more | 3 | Completed | Oct 27, 2014 | 233 |
| NCT01959971Hypercholesterolemia · United States | 1 | Completed | May 2015 | 20 |
| NCT01954394Hypercholesterolemia · United States, Argentina, Austria and more | 3 | Completed | Jun 30, 2017 | 986 |
| NCT01812707Hypercholesterolemia · Japan | 2 | Completed | Jan 2014 | 100 |
| NCT01785329Hypercholesterolemia · United Kingdom | 1 | Completed | Jul 2013 | 60 |
| NCT01670734Hypercholesterolemia · France, Moldova, Republic of | 1 | Completed | May 2013 | 25 |
| NCT01663402Atherosclerosis · United States, Argentina, Australia and more | 3 | Completed | Jan 23, 2018 | 18,924 |
| NCT01644474Hypercholesterolemia · United States, Belgium, Finland and more | 3 | Completed | Jul 2013 | 103 |
| NCT01644188Hypercholesterolemia · United States, Canada, Denmark and more | 3 | Completed | May 2014 | 720 |
| NCT01644175Hypercholesterolemia · United States | 3 | Completed | Apr 2014 | 316 |
| NCT01623115Hypercholesterolemia · United States, Austria, Canada and more | 3 | Completed | Apr 2014 | 486 |
| NCT01617655Hypercholesterolemia · United States, Canada, Netherlands and more | 3 | Completed | May 2014 | 107 |
| NCT01507831Hypercholesterolemia · United States, Argentina, Belgium and more | 3 | Completed | Nov 2014 | 2,341 |
| NCT01448304Hypercholesterolemia · United States | 1 | Completed | Sep 2011 | 24 |
| NCT01448239Hypercholesterolemia · United States | 1 | Completed | May 2011 | 24 |
| NCT01448317Hypercholesterolemia · Japan | 1 | Completed | Jan 2012 | 32 |
| NCT01443650Hypercholesterolemia · United States | 1 | Completed | Nov 2011 | 36 |
| NCT01288469Hypercholesterolemia · United States | 2 | Completed | Sep 2011 | 92 |
| NCT01288443Hypercholesterolemia · United States | 2 | Completed | Dec 2011 | 183 |
How it is read
Names in the registry
- “Alirocumab”, 28 entries
- “alirocumab SAR236553 (REGN727)”, 8 entries
- “Alirocumab SAR236553 (REGN727)”, 2 entries
- “alirocumab”, 2 entries
- “REGN727”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 39 studies
- Hyperlipoproteinemia Type II, 2 studies
- Coronary Artery Disease, 2 studies
- Homozygous Familial Hypercholesterolemia, 1 study
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.